Results 221 to 230 of about 140,577 (292)

Mapping the rare disease stakeholders in India. [PDF]

PLOS Glob Public Health
Chakraborty Choudhury M, George JP, Srinivas PN.   +2 more
europepmc   +1 more source

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

British Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner, Daniela Krepper, Micha Johannes Pilz, Lisa Marie Storz, Maike Thumfart, Johannes Maria Giesinger   +5 more
wiley   +1 more source

An Internet of Things-Based Audio and Radio Connected System Supporting Older Adults With Physical and Cognitive Health Challenges: Qualitative Stakeholder-Informed Design Study. [PDF]

JMIR Form Res
Liu J, Wang X, Shieu B, Garcia DD, Vondenberger A, Xu J, Zhang Y, Monjur M, Wang W, Nirjon S, Svatek R, Gonzales M, Patel N, Song L.   +13 more
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Core outcome set for Traditional Chinese Medicine treatment of adult allergic rhinitis: study protocol. [PDF]

BMJ Open
Xu Y, Jiang J, Zhu H, Sun Y, Jin X.
europepmc   +1 more source

Engaging stakeholders, shaping AI ethics: Targeted engagement in corporate AI ethics statements. [PDF]

PLoS One
Ye M, Friginal E.
europepmc   +1 more source

Understanding the value of virtual care technologies: development of a framework in the veterans health administration. [PDF]

Front Digit Health
Hogan TP, Etingen B, McMahon N, Escudero G, Calkins S, Moussa A, Slightam C, Zulman D, Shimada SL, Robinson SA, Zocchi MS, Shah N, Heyworth L, Newton TJ.   +13 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Community and stakeholder engagement in national priority setting and participatory research for HIV, Tuberculosis, and Malaria programs in Nepal. [PDF]

Res Involv Engagem
Neupane S, Shiwakoti R, Aryal L, Nzima M, Lohar I, Sitaula A, Karmacharya U, Paudel K, Bhattachan A, Devkota S, Bhattarai RK, Adhikari B.   +11 more
europepmc   +1 more source